Radiopharm Theranostics Limited (RADX) Gross margin 2023–2025
Radiopharm Theranostics Limited (RADX) gross margin by fiscal year — reported gross profit divided by reported revenue.
1.1%FY2025 · since FY2023: 100.0% → 1.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 1.1% | -98.9 pp |
| FY2024 | 100.0% | +0.0 pp |
| FY2023 | 100.0% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More RADX financial trends
RADX RevenueRADX Net incomeRADX Net marginRADX Gross profitRADX Operating incomeRADX Operating marginRADX Operating cash flowRADX Free cash flowRADX Capital expendituresRADX Return on equityRADX Stock buybacksRADX Dividends paidRADX Total assetsRADX Total liabilitiesRADX Shareholders’ equityRADX overview →